MedStar Health Launches Participation in Phase 3 MAGNITUDE Gene-Editing Study With First U.S. Heart Patient Treated at MedStar Washington Hospital Center
May 03, 2024
May 03, 2024
WASHINGTON, May 3 (TNSres) -- MedStar Washington Hospital Center, a part of MedStar Health, issued the following news:
* * *
Study examines if gene editing can help people living with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)
* * *
The first U.S. heart patient involved in a study for a new gene-editing therapy directly infused inside the body has successfully been enrolled at MedStar Washington Hospital Center. The pivotal, inter . . .
* * *
Study examines if gene editing can help people living with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)
* * *
The first U.S. heart patient involved in a study for a new gene-editing therapy directly infused inside the body has successfully been enrolled at MedStar Washington Hospital Center. The pivotal, inter . . .